STCube

STCube P/CF

The P/CF (Price-to-Cash-Flow Ratio) of STCube (052020.KQ) as of Oct 24, 2026 is -56.00. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was -47.48 — a change of 17.94% (lower).

P/CF

-56.00

YoY

17.94%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of STCube is 2025 -56.00 . P/CF (Price-to-Cash-Flow Ratio) of STCube was 2024 -47.48 . It decreases by 17.94% lower compared to the previous year.

The STCube P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2018
-185.78 KRW
Jan 1, 2019
-5,737.65 KRW
Jan 1, 2020
-107.59 KRW
Jan 1, 2021
-64.57 KRW
Jan 1, 2022
-68.82 KRW
Jan 1, 2023
-44.99 KRW
Jan 1, 2024
-47.48 KRW
Jan 1, 2025
-56.00 KRW
The STCube P/CF history
YEARP/CFYoY
-56.00+17.94%
-47.48+5.53%
-44.99-34.62%
-68.82+6.57%
-64.57-39.98%
-107.59-98.12%
-5,737.65+2,988.35%
-185.78+90.96%
-97.29-153.30%
182.54-169.07%
-264.27—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

STCube Stock analysis

What does STCube do? STCube Inc. generates revenue through its two business segments. The IT segment distributes CCTV lenses and related components, targeting businesses requiring security solutions. The BT segment develops and licenses immunomodulatory anticancer drug therapeutic candidates, selling to pharmaceutical companies and research institutions. Both segments operate under the company's brand, leveraging its IT and biotechnology expertise. The IT segment focuses on closed-circuit television lens distribution, serving commercial and industrial clients seeking reliable security infrastructure. The BT segment's drug development and licensing activities cater to the pharmaceutical industry, providing innovative therapeutic candidates for cancer treatment. These offerings align with STCube's dual expertise in technology and biotechnology. STCube's revenue streams are derived from product distribution in the IT sector and licensing agreements in the biotechnology sector. The company's clients include businesses needing CCTV components and pharmaceutical firms interested in anticancer drug development. This dual approach allows STCube to serve distinct market segments with specialized solutions. STCube is one of the most popular companies on Eulerpool.

Frequently Asked Questions about STCube stock

P/CF (Price-to-Cash-Flow Ratio) of STCube is -56.00 in 2025.

P/CF (Price-to-Cash-Flow Ratio) of STCube changed from -47.48 to -56.00, representing a 17.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) STCube since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s STCube with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — STCube

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — STCube